Zinc-L-Carnosine
Research reviewed: Up until 03/2026
Zinc-L-Carnosine (Zinc-L-carnosine (Polaprezinc, C₉H₁₂N₃O₃Zn)) is a dietary supplement with 7 published peer-reviewed studies involving 567 participants, researched for Gastric Ulcer Healing, Gut Barrier & Mucosal Protection, H. pylori & Gastritis.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Gastric Ulcer Healing
StrongGut Barrier & Mucosal Protection
ModerateH. pylori & Gastritis
StrongResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Gastric Ulcer Healing
To evaluate zinc-L-carnosine (polaprezinc) for gastric ulcer healing.
Study Type
Randomised, double-blind, controlled
Purpose
To evaluate zinc-L-carnosine (polaprezinc) for gastric ulcer healing.
Dose
150 mg/day zinc-L-carnosine
Participants
289 patients with gastric ulcers
Duration
8 weeks
Results
Zinc-L-carnosine achieved 61% endoscopic ulcer healing at 8 weeks, comparable to cetraxate (56%). Significantly improved pain, heartburn, and nausea.
How They Measured It
Endoscopic ulcer healing rate, symptom improvement
To evaluate zinc-L-carnosine as adjunct to PPI for gastric ulcer healing.
Study Type
Randomised controlled trial
Purpose
To evaluate zinc-L-carnosine as adjunct to PPI for gastric ulcer healing.
Dose
150 mg/day zinc-L-carnosine + standard PPI
Participants
116 patients with gastric ulcers
Duration
8 weeks
Results
Combination of zinc-L-carnosine + PPI achieved significantly higher healing rates (95%) than PPI alone (81%) at 8 weeks. Time to symptom resolution was also faster.
How They Measured It
Endoscopic healing rate, time to healing, symptom resolution
Gut Barrier & Mucosal Protection
To evaluate zinc-L-carnosine on NSAID-induced increases in intestinal permeability.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate zinc-L-carnosine on NSAID-induced increases in intestinal permeability.
Dose
37.5 mg zinc-L-carnosine twice daily
Participants
10 healthy volunteers
Duration
5 days
Results
Zinc-L-carnosine completely prevented indomethacin-induced increase in intestinal permeability. Gut permeability increased 3-fold with NSAID alone but did not increase with zinc-L-carnosine co-administration.
How They Measured It
Intestinal permeability (lactulose/rhamnose ratio), gut injury markers
To evaluate zinc-L-carnosine on exercise-induced gut permeability and endotoxemia.
Study Type
Human clinical study
Purpose
To evaluate zinc-L-carnosine on exercise-induced gut permeability and endotoxemia.
Dose
75 mg zinc-L-carnosine twice daily
Participants
16 healthy trained athletes
Duration
14 days supplementation + exercise test
Results
Zinc-L-carnosine significantly attenuated exercise-induced increases in gut permeability and plasma endotoxin levels. GI symptoms during exercise were also reduced.
How They Measured It
Plasma endotoxin, lactulose/rhamnose ratio, GI symptoms during exercise
To evaluate mechanisms of zinc-L-carnosine on gut mucosal repair.
Study Type
In vitro and clinical study
Purpose
To evaluate mechanisms of zinc-L-carnosine on gut mucosal repair.
Dose
75 mg zinc-L-carnosine per dose
Participants
In vitro wound healing models + 18 patients with GI lesions
Duration
In vitro + single dose clinical
Results
Zinc-L-carnosine stimulated cell migration (wound healing) in vitro and increased protective gastric prostaglandin levels in clinical biopsies. Effect was greater than zinc or L-carnosine alone.
How They Measured It
Cell migration assays (in vitro), gastric biopsy prostaglandin levels (clinical)
H. pylori & Gastritis
To evaluate zinc-L-carnosine as adjunct to H. pylori eradication therapy.
Study Type
Randomised, controlled
Purpose
To evaluate zinc-L-carnosine as adjunct to H. pylori eradication therapy.
Dose
150 mg/day zinc-L-carnosine
Participants
66 H. pylori-positive patients
Duration
12 weeks
Results
Zinc-L-carnosine + triple therapy significantly improved eradication rate (93.2% vs 78.6% triple therapy alone) and showed superior gastritis healing.
How They Measured It
H. pylori eradication rate, gastritis improvement scores
To evaluate zinc-L-carnosine on chronic gastritis symptoms independent of H. pylori.
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate zinc-L-carnosine on chronic gastritis symptoms independent of H. pylori.
Dose
150 mg/day zinc-L-carnosine
Participants
52 patients with chronic non-H. pylori gastritis
Duration
8 weeks
Results
Zinc-L-carnosine significantly reduced gastritis symptom scores and improved endoscopic appearance. Histological inflammation also improved.
How They Measured It
Gastritis symptom score, endoscopic gastritis grade, histological inflammation
Frequently Asked Questions
Common questions about Zinc-L-Carnosine research
There are currently 7 peer-reviewed studies on Zinc-L-Carnosine (Zinc-L-carnosine (Polaprezinc, C₉H₁₂N₃O₃Zn)), involving 567 total participants. Research covers Gastric mucosal protection, Ulcer healing, Gut barrier function and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (6 human studies), and reported outcomes.
Zinc-L-Carnosine has been researched for: Gastric mucosal protection, Ulcer healing, Gut barrier function, H. pylori support. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 6 out of 7 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
